natgillin/translations-raw huggingface dataset:
Patienter skal monitoreres nøje for dosisrelaterede bivirkninger.
Patients should be closely monitored for dose related adverse reactions.
Virkningen af behandling med 6-mercaptopurin på fertilitet hos mennesker kendes ikke, men der er rapporter om, at både mænd og kvinder har fået børn efter at være blevet behandlet som børn eller unge.
The effect of 6-mercaptopurine therapy on human fertility is unknown but there are reports of successful fatherhood/motherhood after receiving treatment during childhood or adolescence.
til 7 pædiatriske patienter var biotilgængeligheden i gennemsnit 16 % af den administrerede dosis inden for et område på 5 til 37 %.
When administered orally at a dosage of 75 mg/m2 to 7 paediatric patients, the bioavailability averaged 16% of the administered dose, with a range of 5 to 37%.
Evidensen for 6-mercaptopurins teratogenicitet hos mennesker er usikker.
Evidence of the teratogenicity of 6-mercaptopurine in humans is equivocal.
Du må ikke stoppe med at tage din medicin, medmindre lægen siger det.
Do not stop taking your medicine unless your doctor tells you to or you may get a relapse of your condition.
Cytotoksicitet og hæmatologisk monitorering
Cytotoxicity and haematological monitoring
Aktivt stof: mercaptopurin (som monohydrat).
The active substance is mercaptopurine (as monohydrate).
Der er lav optagelse af 6-mercaptopurin i cerebrospinalvæsken.
There is low entry of 6-mercaptopurine into the cerebrospinal fluid.
Både TIMP og mTIMP hæmmer fosforibosylpyrofosfat-amidotransferase, et enzym, som er væsentligt i de novo purinsyntese.
Both TIMP and mTIMP are inhibitors of phosphoribosyl pyrophosphate amidotransferase, an enzyme which is important in de novo purine synthesis.
Hepatosplenisk T-celle lymfom er rapporteret hos patienter med inflammatorisk tarmsygdom* behandlet med azathioprin (prodrug til to 6-mercaptopurin) eller 6-mercaptopurin, enten med eller uden samtidig behandling med antistof mod anti-TNF-alfa.
Hepatosplenic T-cell lymphoma has been reported in patients with inflammatory bowel disease* treated with azathioprine (the prodrug to 6-mercaptopurine) or 6-mercaptopurine, either with or without concomitant treatment with anti-TNF alpha antibody.
6-mercaptopurin gennemgår også S-methylering af enzymet thiopurin S-methyltransferase (TPMT), hvilket giver methylmercaptopurin, som er inaktivt.
6-mercaptopurine is also subject to S-methylation by the enzyme thiopurine S-methyltransferase (TPMT), yielding methylmercaptopurine, which is inactive.
Det første skridt katalyseres af hypoxanthin-guanin fosforibosyltransferase som giver thioinosin-monofosfat (TIMP).
The first step is catalysed by hypoxanthine-guanine phosphoribosyl transferase yielding thioinosine monophosphate (TIMP).
Urinsyre er et naturligt kemikalie i kroppen, og niveauet af urinsyre kan stige, mens du tager Xaluprine.
Uric acid is a natural body chemical, levels of which can rise while taking Xaluprine.
Hæmatologiske parametre bør nøje monitoreres under behandlingen.
Careful monitoring of haematological parameters should be conducted during therapy.
- Tag ikke Xaluprine, hvis du er overfølsom (allergisk) over for mercaptopurin eller et af de øvrige indholdsstoffer (se pkt.
- Do not take Xaluprine if you are allergic (hypersensitive) to mercaptopurine or any of the other ingredients of Xaluprine (see section 6).
Stigninger i kromosomafvigelser blev observeret i de perifere lymfocytter hos leukæmipatienter, hos patienter med renalcellecarcinom, som fik en ikke defineret dosis 6-mercaptopurin, og hos patienter med kronisk nyresygdom behandlet med doser på 0,4 - 1,0 mg/kg/dag.
Increases in chromosomal aberrations were observed in the peripheral lymphocytes of leukaemic patients, in a renal cell carcinoma patient who received an unstated dose of 6-mercaptopurine and in patients with chronic renal disease treated at doses of 0.4 - 1.0 mg/kg/day.
Du kan tage medicinen sammen med mad eller på tom mave, men metoden skal være den samme hver dag.
Your can take your medicine with food or on an empty stomach but the choice of method should be consistent from day to day.
Der findes personer med en nedarvet mangel på TPMT-enzymaktivitet, som er meget følsomme over for 6-mercaptopurins myelosupprimerende virkning, og som har en tendens til at udvikle hurtig knoglemarvsdepression efter initiering af behandling med 6-mercaptopurin.
There are individuals with an inherited deficiency of the TPMT enzyme activity who are very sensitive to the myelosuppresive effect of 6-mercaptopurine and prone to developing rapid bone marrow depression following the initiation of treatment with 6-mercaptopurine.
Almindelige (rammer mindre end 1 ud af 10) - utilpashed (kvalme eller opkastning) - leverskade - kan vise sig ved blodprøver - et fald i antallet af røde blodlegemer, som kan gøre dig træt, svag eller stakåndet - kaldes anæmi - tab af appetit - diarré - betændelse i mundhulen (stomatitis)
Common (affects less than 1 in 10 people) - feeling or being sick (nausea or vomiting) - liver damage - this may show up in blood tests - a drop in red blood cells which may make you tired, weak or breathless (called anaemia) - loss of appetite - diarrhoea - inflammation of the mouth (stomatitis)
6-mercaptopurin metaboliseres af det polymorfiske TPMT-enzym.
6-mercaptopurine is metabolised by the polymorphic TPMT enzyme.
De histologiske fund hos mennesker har vist hepatisk nekrose og galdestase.
The histological findings in man have shown hepatic necrosis and biliary stasis
Spildt suspension skal straks tørres op.
Spillages must be wiped immediately.
Koncentreret hindbærsaft Sakkarose
Concentrated raspberry juice Sucrose
Cytotoksiske midler kan reducere tarmenes absorption af fenytoin.
Cytotoxic agents may decrease the intestinal absorption of phenytoin.
Undgå, at Xaluprine kommer i kontakt med hud, øjne eller næse.
Avoid contact of Xaluprine with your skin, eyes or nose.
Xanthinoxidase er det væsentligste katabolenzym og konverterer 6-mercaptopurin til den inaktive metabolit, 6-thiourinsyre.
Xanthine oxidase is the main catabolic enzyme and it converts the 6-mercaptopurine into the inactive metabolite, 6-thiouric acid.
Xaluprine indeholder aspartam (E951), som indeholder en kilde til fenylalanin.
Xaluprine contains aspartame (E951) which contains a source of phenylalanine.
Du skal bruge denne sprøjte, hvis den samlede mængde, du skal tage, er mere end 1 ml (hver graduering af 0,2 ml indeholder 4 mg mercaptopurin).
You should use this one if the total amount you have to take is more than 1 ml (each graduation of 0.2 ml contains 4 mg of mercaptopurine).
INFORMATION I BRAILLESKRIFT Xaluprine 20 mg/ml
INFORMATION IN BRAILLE Xaluprine 20 mg/ml
*inflammatorisk tarmsygdom er en uautoriseret indikation.
*inflammatory bowel disease (IBD) is an unlicensed indication
Den større 5 ml sprøjte (hvid), markeret fra 1 ml til 5 ml, er til opmåling af doser, som er større end 1 ml.
The larger 5 ml syringe (white), marked 1 ml to 5 ml, is for measuring doses of more than 1 ml.
Sjældne (rammer mindre end 1 ud af 1.000) - hårtab - hos mænd: midlertidigt lavt sædcelletal - hævelser i ansigtet - forskellige former for kræft, herunder blodkræft, lymfekræft og hudkræft
Rare (affects less than 1 in 1,000 people) - hair loss - in men: temporary low sperm count - swollen face - various types of cancers including blood, lymph and skin cancers
Serumniveauet af antiepileptika skal overvåges nøje under behandling med Xaluprine, og dosen skal justeres efter behov.
Serum antiepileptic levels should be closely monitored during treatment with Xaluprine, making dose adjustments as necessary.
Disse patienter kræver generelt en dosisreduktion; særligt de patienter, der er homozygote for NUDT15-varianten (se pkt.
These patients generally require dose reduction; particularly those being NUDT15 variant homozygotes (see 4.4).
Patienter med et nedarvet, muteret NUDT15-gen har en øget risiko for alvorlig 6mercaptopurintoksicitet, såsom tidlig leukopeni og alopeci, fra konventionelle doser thiopurinbehandling.
Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy.
Forbigående udbredt oligospermi er rapporteret efter eksponering for 6-mercaptopurin i kombination med kortikosteroider.
Transient profound oligospermia has been reported following exposure to 6-mercaptopurine in combination with corticosteroids.
Bivirkningerne er angivet ud fra systemorganklasse og hyppighed: meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1.000 til < 1/100), sjælden (≥ 1/10.000 til < 1/1.000) og meget sjælden (< 1/10.000).
(≥1/1000 to < 1/100), rare (≥1/10,000 to < 1/1000) and very rare (< 1/10,000).
Hvis du tager for meget Xaluprine, skal du straks søge læge eller tage på hospitalet.
If you take more Xaluprine than you should, tell your doctor or go to a hospital immediately.
- andre cytotoksiske lægemidler (kemoterapi) - når de anvendes sammen med Xaluprine, er der større risiko for bivirkninger som for eksempel anæmi - allopurinol eller febuxostat (anvendes til behandling af urinsyregigt) - orale antikoagulerende midler (anvendes til at fortynde blodet) - olsalazin eller mesalazin (anvendes til en tarmlidelse ved navn ulcerativ colitis)
- other cytotoxic medicines (chemotherapy) - when used with Xaluprine there is a greater chance of side effects, such as anaemia - allopurinol or febuxostat (used to treat gout) - oral anticoagulants (used to thin the blood) - olsalazine or mesalazine (used for a bowel disorder called ulcerative colitis) - sulfasalazine (used for rheumatoid arthritis or ulcerative colitis).
Xaluprine kan tages sammen med mad eller på tom mave, men patienter bør standardisere deres administrationsmetode.
Xaluprine may be taken with food or on an empty stomach, but patients should standardise the method of administration.
En mulig forbindelse mellem reduceret TPMT-aktivitet og sekundær leukæmi og myelodysplasi er rapporteret hos personer, som fik 6-mercaptopurin i kombination med andre cytotoksiske midler (se pkt.
A possible association between decreased TPMT activity and secondary leukaemias and myelodysplasia has been reported in individuals receiving 6-mercaptopurine in combination with other cytotoxics (see section 4.8).
En kombination af flere immunsuppressiva administreret samtidigt øger risikoen for Epstein-Barr-virus (EBV) -relaterede lymfoproliferative sygdomme.
A combination of multiple immunosuppressants, given concomitantly increases the risk of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders.
Tag altid Xaluprine nøjagtigt efter lægens eller apotekspersonalets anvisning.
Always take Xaluprine exactly as your doctor or pharmacist has told you.
Nogle patienter med inflammatorisk tarmsygdom, som har fået 6-mercaptopurin, har udviklet en sjælden og aggressiv form for kræft, der kaldes hepatosplenisk T-celle lymfom (se punk.
Some patients with inflammatory bowel disease who have received 6-mercaptopurine have developed a rare and aggressive type of cancer called Hepatosplenic T-cell Lymphoma (see section 4, Possible side effects).
Kombination med xanthinoxidasehæmmere
Combination with xanthine oxidase inhibitors
Neoplasmer, herunder lymfoproliferative sygdomme, hudcancer (melanom og non-melanom), sarkomer (Kaposi og non-Kaposi) og cervixcancer in situ (se pkt.
Neoplasms including lymphoproliferative disorders, skin cancers (melanomas and non-melanomas), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ (see section 4.4).
Risikoen for overdosering er ligeledes øget, når xanthinoxidasehæmmere gives samtidig med 6-mercaptopurin (se pkt.
The risk of overdose is also increased when xanthine oxidase inhibitors is being given concomitantly with 6-mercaptopurine (see section 4.5).
Den mindste 1 ml sprøjte (violet), markeret fra 0,1 til 1,0 ml, er til opmåling af doser, som er mindre end eller lig med 1 ml.
The smaller 1 ml syringe (purple), marked from 0.1 ml to 1 ml, is for measuring doses of less than or equal to 1 ml.
Meget sjældne (rammer mindre end 1 ud af 10.000) - en anden type leukæmi end den, der behandles - sår på tarmene
Very rare (affects less than 1 in 10,000 people) - a different type of leukaemia to that being treated - ulcers in the intestines
Der er indberettet tilfælde af pankreatitis med en hyppighed på ≥ 1/100 til < 1/10 (“almindelig”) hos patienter, der behandles for den ikke-godkendte indikation inflammatorisk tarmsygdom.
Pancreatitis in off-label treatment of patients with inflammatory bowel disease Pancreatitis has been reported to occur at a frequency of ≥ 1/100 to < 1/10 (“common”) in patients treated for the unlicensed indication inflammatory bowel disease.
Der foreligger ikke tilstrækkelig nyere klinisk dokumentation for mercaptopurin, som kan understøtte nøjagtig påvisning af hyppigheden af bivirkninger.
For mercaptopurine there is a lack of modern clinical documentation which can serve as support for accurately determining the frequency of adverse reactions.
Andre xanthinoxidasehæmmere skal undgås (se pkt.
Other xanthine oxidase inhibitors should be avoided (see section 4.5).
Der medfølger to dosissprøjter (en violet sprøjte gradueret til 1 ml og en hvid sprøjte gradueret til 5 ml) til nøjagtig opmåling af den ordinerede dosis oral suspension.
Two dosing syringes (a purple syringe graduated to 1 ml and a white syringe graduated to 5 ml) are provided for accurate measurement of the prescribed dose of the oral suspension.
Utilsigtet indtagelse kan være dødelig for børn.
Accidental ingestion can be lethal for children.
Forældre og plejepersoner bør undgå, at Xaluprine kommer i kontakt med hud eller slimhinder.
Parents and care givers should avoid Xaluprine contact with skin or mucous membrane.
Det er i alle tilfælde nødvendigt at monitorere blodtallene nøje.
In any case, close monitoring of blood counts is necessary.
Du skal bruge denne sprøjte, hvis den samlede mængde, du skal tage, er mindre end eller lig med 1 ml (hver graduering af 0,1 ml indeholder 2 mg mercaptopurin).
You should use this one if the total amount you have to take is less than or equal to 1 ml (each graduation of 0.1 ml contains 2 mg of mercaptopurine).
6-mercaptopurin er som andre antimetabolitter mutagen og forårsager kromosomafvigelser in vitro og in vivo hos mus og rotter.
6-mercaptopurine, in common with other antimetabolites, is mutagenic and causes chromosomal aberrations in vitro and in vivo in mice and rats.
Derfor kan Xaluprine tages sammen med mad eller på tom mave, men patienter bør standardisere deres administrationsmetode.
Therefore, Xaluprine may be taken with food or on an empty stomach, but patients should standardise the method of administration.
De kræver generelt en dosisreduktion, særligt de patienter, der er homozygote for NUDT15-varianten (se pkt.
They generally require dose reduction, particularly those being NUDT15 variant homozygotes (see 4.2).
Tag engangshandsker på, inden du håndterer Xaluprine.
Put on disposable hand gloves before handling Xaluprine.
Allopurinol og andre xanthinoxidasehæmmere reducerer 6-mercaptopurins katabolismehastighed.
Allopurinol and other xanthine oxidase inhibitors decrease the rate of catabolism of 6-mercaptopurine.
Følg nedenstående instruktioner, når du tager medicinen:
When you use the medicine follow the instructions below:
Patienten skal instrueres i omgående at ophøre med at tage Xaluprine, hvis der er tegn på gulsot (se pkt.
The patient should be instructed to discontinue Xaluprine immediately if jaundice becomes apparent (see section 4.8).
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) Oral suspension.
PHARMACEUTICAL FORM AND CONTENTS Oral suspension.
Patienter i immunsupprimerende behandling, herunder med mercaptopurin, har en øget risiko for at udvikle lymfoproliferative sygdomme og andre maligniteter, især hudcancer (melanom og non-melanom), sarkomer (Kaposi og non-Kaposi) og cervixcancer in situ.
Patients receiving immunosuppressive therapy, including mercaptopurine, are at an increased risk of developing lymphoproliferative disorders and other malignancies, notably skin cancers (melanoma and non-melanoma), sarcomas (Kaposi's and non-Kaposi's) and uterine cervical cancer in situ.
Hvis du holder op med at tage Xaluprine
If you stop taking Xaluprine
6-merpactopurins intracellulære anabolisme katalyseres af flere enzymer til dannelse af 6-thioguanin-nukleotider (TGN'er), men der dannes flere forskellige midlertidige TGN'er i processen mod TGN'er.
The intracellular anabolism of 6-merpactopurine is catalysed by several enzymes to eventually form 6-thioguanine nucleotides (TGNs), but a variety of intermediary TGNs are formed en route to the TGNs.
Der er indberettet tilfælde af neutropenisk sepsis hos patienter med ALL, der fik 6-mercaptopurin.
Cases of neutropenic sepsis have been reported in patients receiving 6-mercaptopurine for ALL.
TPMT katalyserer imidlertid også S-methyleringen af den primære nukleotide metabolit, TIMP, og danner methylthioinosin-monofosfat (mTIMP).
TPMT also catalyses the S-methylation of the principle nucleotide metabolite, TIMP, to form methylthioinosine monophosphate (mTIMP).
Opbevaring - Opbevar lægemidlet utilgængeligt for børn, helst i et låst skab.
- Keep this medicine out of the sight and reach of children, preferably in a locked cupboard.
Xaluprine indeholder mercaptopurin.
Xaluprine contains mercaptopurine.
Behandling med 6-mercaptopurin forårsager knoglemarvssuppression, som fører til leukopeni og trombocytopeni og mindre hyppigt til anæmi.
Treatment with 6-mercaptopurine causes bone marrow suppression leading to leucopenia and thrombocytopenia and, less frequently, to anaemia.
Patienter skal monitoreres nøje for dosisrelaterede bivirkninger (se pkt.
Patients should be closely monitored for dose related adverse reactions (see section 4.4).
Kontrollér, at hætten er lukket tæt.
Ensure that the cap is tightly closed.
Kontraception til mænd og kvinder.
Contraception in males and females
Samtidig administration af vaccine mod gul feber er kontraindiceret på grund af risikoen for dødelig sygdom hos immunkompromitterede patienter (se pkt.
Effects of mercaptopurine on other medicinal products Concomitant administration of yellow fever vaccine is contraindicated, due to the risk of fatal disease in immunocompromised patients (see section 4.3)
Flere medfødte abnormiteter har været rapporteret efter behandling af moderen med 6-mercaptopurin i kombination med andre kemoterapimidler.
Multiple congenital abnormalities have been reported following maternal 6-mercatopurine treatment in combination with other chemotherapy agents.
Makrofag-aktiveringssyndrom
Macrophage activation syndrome
Da farmakokinetikken for 6-mercaptopurin ikke er formelt undersøgt ved nyreinsufficiens, kan der ikke gives nogen specifikke dosisanbefalinger.
Since 6-mercaptopurine pharmacokinetics has not been formally studied in renal impairment, no specific dose recommendations can be given.
Andre bivirkninger (ikke kendt hyppighed) - en sjælden type kræft (hepatosplenisk T-celle lymfom (se punkt 2, Advarsler og forsigtighedsregler) - Overfølsomhed over for sollys, der giver hudreaktioner
Other side effects (the frequency is unknown) - a rare type of cancer (hepatosplenic T-cell lymphoma), (see section 2, Warnings and
1 ml suspension indeholder 3 mg aspartam, 1 mg methylhydroxybenzoat (som natriumsalt), 0,5 mg ethylhydroxybenzoat (som natriumsalt) og sakkarose (spor).
One ml of suspension contains 3 mg aspartame, 1 mg methyl hydroxybenzoate (as the sodium salt), 0.5 mg ethyl hydroxybenzoate (as the sodium salt) and sucrose (trace).
Lægemidlet indeholder også natriummethylparahydroxybenzoat og natriumethylparahydroxybenzoater, som kan give allergiske reaktioner (muligvis forsinkede).
It also contains sodium methyl parahydroxybenzoate and sodium ethyl parahydroxybenzoate which may cause allergic reaction (possibly delayed).
Patienter med et nedarvet, muteret NUDT15-gen har en øget risiko for alvorlig 6mercaptopurintoksicitet (se pkt.
Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, (see 4.4).
Da farmakokinetikken for 6-mercaptopurin ikke er formelt undersøgt ved leverinsufficiens, kan der ikke gives nogen specifikke dosisanbefalinger.
Since 6-mercaptopurine pharmacokinetics has not been formally studied in hepatic impairment, no specific dose recommendations can be given.
De vigtigste bivirkninger ved behandling med 6-mercaptopurin er knoglemarvssuppression, som fører til leukopeni og trombocytopeni.
The main adverse reaction of treatment with 6-mercaptopurine is bone marrow suppression leading to leucopenia and thrombocytopenia.
FREMSTILLERENS BATCHNUMMER Parti:
BATCH NUMBER Lot:
Din læge eller apotekspersonalet vil fortælle dig, hvilken sprøjte du skal bruge, afhængigt af den ordinerede dosis.
Your doctor or pharmacist will advise which syringe to use depending on the dose that has been prescribed.
Når allopurinol og Xaluprine administreres samtidig, er det essentielt, at der kun gives en fjerdedel af den sædvanlige dosis Xaluprine, da allopurinol reducerer 6-mercaptopurins metaboliseringshastighed via xanthinoxidase.
Effects of other medicinal products on mercaptopurine When allopurinol and Xaluprine are administered concomitantly it is essential that only a quarter of the usual dose of Xaluprine is given since allopurinol decreases the rate of metabolism of 6-mercaptopurine via xanthine oxidase.
Xaluprine er en lyserød til brun oral suspension.
What Xaluprine looks like and contents of the pack Xaluprine is a pink to brown oral suspension.
Du må ikke amme, mens du tager Xaluprine.
Do not breast-feed while taking Xaluprine.
Det skal du vide, før du begynder at tage Xaluprine
What you need to know before you take Xaluprine
Der er rapporteret om hæmning af warfarins antikoagulerende virkning, når midlet gives samtidig med 6-mercaptopurin.
Inhibition of the anticoagulant effect of warfarin, when given with 6-mercaptopurine, has been reported.
Galdestase, hepatotoksicitet
Biliary stasis, hepatotoxicity
KVALITATIV OG KVANTITATIV SAMMENSÆTNING 1 ml suspension indeholder 20 mg mercaptopurin (som monohydrat).
QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of suspension contains 20 mg mercaptopurine (as monohydrate).
1 ml suspension indeholder 20 mg mercaptopurin-monohydrat.
One ml of suspension contains 20 mg of mercaptopurine monohydrate.
Din læge eller apotekspersonalet fortæller dig, hvilken sprøjte du skal bruge afhængig af den ordinerede dosis.
Your doctor or pharmacist will advise which syringe to use depending on the dose that has been prescribed
Xaluprine indeholder saccharose.
Xaluprine contains sucrose.
Knoglemarvssuppression, leukopeni og trombocytopeni
Bone marrow suppression; leucopenia and thrombocytopenia
Xaluprine indeholder:
What Xaluprine contains
Xaluprine indeholder også natriummethylparahydroxybenzoat (E219) og natriumethylparahydroxy-benzoat (E215), som kan give allergiske reaktioner (muligvis forsinkede).
Xaluprine also contains sodium methyl parahydroxybenzoate (E219) and sodium ethyl parahydroxybenzoate (E215) which may cause allergic reactions (possibly delayed).
6-mercaptopurin-metabolitter hæmmer den indbyrdes konvertering af de novo-purinsyntese og purinnukleotider.
The 6-mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions.
Ikke almindelige (rammer mindre end 1 ud af 100) - mundsår - betændelse i bugspytkirtlen - ledsmerter - hududslæt - feber - permanent leverskade (levernekrose)
Uncommon (affects less than 1 in 100 people) - mouth ulcers - inflamed pancreas - joint pain - skin rash - fever - permanent damage to the liver (hepatic necrosis)
Brug af Xaluprine sammen med mad og drikke Xaluprine kan tages sammen med mad eller på tom mave.
Xaluprine may be taken with food or on an empty stomach.
Der er indberettet tilfælde af symptomatisk hypoglykæmi hos børn med ALL, som fik 6-mercaptopurin (se pkt.
Cases of symptomatic hypoglycaemia have been reported in children with ALL receiving 6-mercaptopurine (see section 4.8).